Cogent Biosciences Inc. (COGT) just got some welcome news from regulators. On Monday, the FDA handed the company breakthrough therapy designation for its drug bezuclastinib when combined with sunitinib, targeting patients with gastrointestinal stromal tumors who've already been through at least one round of treatment.
These aren't just any cancer patients. The trial focused on people with GIST who'd previously received Novartis AG's (NVS) Gleevec (imatinib), which is typically the first-line therapy. When that stops working, options narrow considerably. Enter Cogent's combination approach, which pairs its experimental drug with sunitinib, a treatment Pfizer Inc. (PFE) markets as Sutent.
The Numbers Tell a Compelling Story
The breakthrough designation stems from results in the PEAK trial, where bezuclastinib combined with sunitinib delivered what researchers call a "substantial and highly statistically significant" benefit. Translation: It worked, and it worked well. The combination slashed the risk of disease progression or death by 50% compared to the current standard of care.
Looking at median progression-free survival, patients on the combination therapy went 16.5 months before their disease progressed, compared to just 9.2 months for those taking sunitinib alone. That's nearly double the time without progression, which matters enormously to patients dealing with advanced cancer.
The safety profile looked solid too. The combination was well tolerated, and researchers didn't spot any new safety concerns beyond what's already known about sunitinib. That's important because cancer treatments often face the challenge of balancing efficacy against tolerability.
Fast-Tracking Toward Approval
Earlier this month, the FDA agreed to accept Cogent's application through its Real-Time Oncology Review program. This expedited pathway lets companies submit portions of their New Drug Application in stages rather than waiting to compile everything at once. The FDA can start reviewing clinical data while the company finalizes other components, potentially shaving months off the review timeline.
Cogent expects to kick off the RTOR process immediately and complete its full NDA submission by April 2026. The company also plans to present comprehensive results from the PEAK trial at a major medical conference sometime in the first half of next year, giving the medical community a deeper look at the data.
What's Coming Next
Cogent isn't stopping with this indication. By mid-2026, the company expects to launch a Phase 2 trial testing the bezuclastinib and sunitinib combination in first-line GIST patients with exon 9 mutations. These would be patients who either haven't started imatinib yet or just recently began treatment with it.
The company is also pursuing another indication entirely. In December 2025, Cogent submitted a separate NDA to the FDA for bezuclastinib in non-advanced systemic mastocytosis. That submission draws on clinical data from the SUMMIT pivotal trial and follows an earlier breakthrough therapy designation for bezuclastinib in certain mastocytosis patient populations, including those who've previously received Sanofi SA's (SNY) Ayvakit (avapritinib).
For a company with multiple programs advancing toward potential approval, it's a busy stretch ahead. The regulatory momentum suggests Cogent's approach to targeting specific cancer mutations is resonating with both the FDA and clinical trial results.
Price Action: COGT stock closed up 1.87% at $37.35 on Monday.
